↑ 薬物リストへ　← 戻る

Lanreotide acetate    (DrugBank: Lanreotide, Acetate)

4 diseases
告示番号疾患名（ページ内リンク）臨床試験数
67多発性嚢胞腎1
73下垂体性TSH分泌亢進症1
85特発性間質性肺炎1
298遺伝性膵炎1

67. 多発性嚢胞腎　［臨床試験数：186，薬物数：196（DrugBank：47），標的遺伝子数：35，標的パスウェイ数：146］
Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 186 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2011-005017-37-NL
(EUCTR)		30/05/201221/05/2012To investigate the effect of Lanreotide on renal function decline in ADPKD patientsA randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume.
MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]		Trade Name: Somatuline Autogel
Product Name: Lanreotide
Product Code: BIM 23014
INN or Proposed INN: Lanreotide
Other descriptive name: LANREOTIDE ACETATE		DIPAK ConsortiumNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		Netherlands

73. 下垂体性TSH分泌亢進症　［臨床試験数：1，薬物数：3（DrugBank：2），標的遺伝子数：0，標的パスウェイ数：0］
Searched query = "TSH-secreting pituitary adenoma", "Pituitary TSH secretion hyperthyroidism"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-JapicCTI-173772
22/1/201815/11/2017Phase 3 Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenomaPhase 3, Open-label Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma TSH-secreting pituitary adenomaIntervention name : Lanreotide Acetate
INN of the intervention : Lanreotide
Dosage And administration of the intervention : Deep subcutaneous administration of 60 mg, 90 mg or 120 mg of lanreotide once every 4 weeks.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -		TEIJIN PHARMA LIMITEDNULLcomplete20BOTH8Phase 3Japan

85. 特発性間質性肺炎　［臨床試験数：514，薬物数：377（DrugBank：108），標的遺伝子数：97，標的パスウェイ数：204］
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 514 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2011-003687-78-IT
(EUCTR)		21/02/201205/03/2012Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF)Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) - IPF/LANREOTIDE/2011-01 Idiopathic Pulmonary Fibrosis
MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]		INN or Proposed INN: LANREOTIDE ACETATE
Product Name: Gallium68-Dota-Noc
Product Code: NA
INN or Proposed INN: NA
Other descriptive name: NA		AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		Italy

298. 遺伝性膵炎　［臨床試験数：93，薬物数：168（DrugBank：51），標的遺伝子数：48，標的パスウェイ数：134］
Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 93 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2009-016082-29-BE
(EUCTR)		10/03/201025/11/2009Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPPRole of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP Paraduodenal pancreatitis
MedDRA version: 12.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis		Trade Name: Somatuline Autogel 90 mg
Other descriptive name: LANREOTIDE ACETATE		Erasme hospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		60Belgium